前列地尔联合保肝药物治疗肝损伤的临床疗效分析(1)
[摘要] 目的 分析前列地爾联合保肝药物治疗肝损伤的临床疗效。方法 便利选取2016年6月—2019年1月在该院接受肝损伤治疗的患者62例，随机数字法分为对照组(31例)和观察组(31例)，对照组采用保肝药物(甘草酸二胺)进行治疗，而观察组在对照组的基础上采用前列地尔进行治疗。比较治疗前后两组谷氨酰转肽酶(GGT)、谷丙转氨酶(ALT)及总胆红素(TBIL)等肝功能指标水平和肿瘤坏死因子(TNF-α)及白细胞介素-8(IL-8)等炎症因子水平的变化情况，同时比较治疗后两组的临床疗效及不良反应。 结果 观察组临床总有效率96.77%高于对照组77.42%，差异有统计学意义(χ2=5.170，P<0.05);治疗后两组的GGT、ALT及TBIL等肝功能指标水平和TNF-α、IL-8等炎症因子指标水平均低于治疗前，且观察组优于对照组，差异有统计学意义(P<0.05);治疗后观察组的不良反应率6.45%低于对照组的9.68%，但差异无统计学意义(χ2=0.220，P>0.05)。结论 采用前列地尔联合保肝药物对肝损伤的临床疗效有显著的提升，能更有效地改善肝功能及降低炎症因子水平，安全性高，具有一定的推广使用价值。
[关键词] 前列地尔;保肝药物;肝功能;炎症因子
[中图分类号] R277 [文献标识码] A [文章编号] 1674-0742(2019)11(a)-0090-03
Clinical Efficacy of Alprostadil Combined with Liver-protecting Drugs in the Treatment of Liver Injury
WANG Yan-mei
Department of Gastroenterology， Tongshan District People's Hospital， Xuzhou， Jiangsu Province， 221006 China
[Abstract] Objective To analyze the clinical efficacy of alprostadil combined with liver-protecting drugs in the treatment of liver injury. Methods A total of 62 patients who underwent liver injury treatment in the hospital from June 2016 to January 2019 were Convenient selected and randomly divided into the control group (31 cases) and the observation group (31 cases). The liver drug (diammonium glycyrrhizinate) was treated， and the observation group was treated with alprostadil on the basis of the control group. Comparison of liver function indexes such as glutamyl transpeptidase (GGT)， alanine aminotransferase (ALT) and total bilirubin (TBIL) and tumor necrosis factor (TNF-α) and interleukin-8 (IL-8) before and after treatment. and other changes in inflammatory factors levels， while comparing the clinical efficacy and adverse reactions of the two groups after treatment. Results The total effective rate 96.77% in the observation group was higher than that in the control group 77.42%. The difference was statistically significant (χ2=5.170， P<0.05). The levels of liver function indexes such as GGT， ALT and TBIL in the two groups after treatment. The levels of inflammatory factors such as TNF-α and IL-8 were lower than those before treatment， and the observation group was superior to the control group. The difference was statistically significant (P<0.05). The adverse reaction rate of the observation group was 6.45% after treatment. The control group was 9.68%， but the difference was not statistically significant (χ2=0.220， P>0.05). Conclusion The clinical efficacy of alprostadil combined with liver-protecting drugs on liver injury has been significantly improved， it can improve liver function more effectively， and reduce the level of inflammatory factors. It has high safety and has certain promotion and use value., 百拇医药(王艳梅)
[关键词] 前列地尔;保肝药物;肝功能;炎症因子
[中图分类号] R277 [文献标识码] A [文章编号] 1674-0742(2019)11(a)-0090-03
Clinical Efficacy of Alprostadil Combined with Liver-protecting Drugs in the Treatment of Liver Injury
WANG Yan-mei
Department of Gastroenterology， Tongshan District People's Hospital， Xuzhou， Jiangsu Province， 221006 China
[Abstract] Objective To analyze the clinical efficacy of alprostadil combined with liver-protecting drugs in the treatment of liver injury. Methods A total of 62 patients who underwent liver injury treatment in the hospital from June 2016 to January 2019 were Convenient selected and randomly divided into the control group (31 cases) and the observation group (31 cases). The liver drug (diammonium glycyrrhizinate) was treated， and the observation group was treated with alprostadil on the basis of the control group. Comparison of liver function indexes such as glutamyl transpeptidase (GGT)， alanine aminotransferase (ALT) and total bilirubin (TBIL) and tumor necrosis factor (TNF-α) and interleukin-8 (IL-8) before and after treatment. and other changes in inflammatory factors levels， while comparing the clinical efficacy and adverse reactions of the two groups after treatment. Results The total effective rate 96.77% in the observation group was higher than that in the control group 77.42%. The difference was statistically significant (χ2=5.170， P<0.05). The levels of liver function indexes such as GGT， ALT and TBIL in the two groups after treatment. The levels of inflammatory factors such as TNF-α and IL-8 were lower than those before treatment， and the observation group was superior to the control group. The difference was statistically significant (P<0.05). The adverse reaction rate of the observation group was 6.45% after treatment. The control group was 9.68%， but the difference was not statistically significant (χ2=0.220， P>0.05). Conclusion The clinical efficacy of alprostadil combined with liver-protecting drugs on liver injury has been significantly improved， it can improve liver function more effectively， and reduce the level of inflammatory factors. It has high safety and has certain promotion and use value., 百拇医药(王艳梅)